With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

GSK (GSK.L) expects to deliver annual sales and profit growth towards the top end of its forecasts after beating ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

FTSE 100 reaction as HSBC sees profits drop, Nationwide launches benefits line - Stock market news and latest business and ...

Swiss banking giant UBS said Wednesday that its net profit doubled in the second quarter thanks to a surge in transactions ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

The FTSE 100 has continued to notch fresh highs, as UK stocks have been swept in broader market optimism around developments on US tariffs.